MOS
SUPN icon

MGO One Seven’s Supernus Pharmaceuticals SUPN Stock Holding History

MGO One Seven’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-5,558
Closed -$201K – 895
2023
Q1 		$201K Buy
+5,558
New +$214K 0.01% 792

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MGO One Seven's SUPN Position: Q2 2023 in Review

MGO One Seven sold out of Supernus Pharmaceuticals (SUPN) in Q2 2023, closing a stake of 5,558 shares — an estimated $201K sold.

MGO One Seven first reported a position in SUPN in Q1 2023 and held it in 1 quarter. The position peaked at $201K in Q1 2023. 249 funds tracked by Wall St. Rank hold SUPN as of Q2 2023.

  • MGO One Seven reported no remaining Supernus Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • MGO One Seven sold 5,558 Supernus Pharmaceuticals shares in Q2 2023, an estimated $201K.
  • MGO One Seven first reported a position in Supernus Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • MGO One Seven's Supernus Pharmaceuticals position peaked at $201K in Q1 2023.
  • 249 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2023.

Based on MGO One Seven's 13F filing for Q2 2023, filed 11 Aug 2023.